Anaphylaxis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Anaphylaxis is a severe, systemic hypersensitivity reaction that is rapid in onset and characterized by life-threatening airway, breathing, and/or circulatory problems, and that is usually associated with skin and mucosal changes. Anaphylaxis is a severe, systemic hypersensitivity reaction that is rapid in onset and characterized by life-threatening airway, breathing, and/or circulatory problems, and that is usually associated with skin and mucosal changes. Caused by the interaction of a foreign antigen with specific IgE antibodies found on tissue mast cells and peripheral blood basophils. The subsequent release of histamine and other bioactive mediators caused by this interaction results in smooth muscle spasm, bronchospasm, mucosal edema, and inflammation, and increase capillary permeability. These systemic changes characteristically show clinical manifestations in seconds or minutes of antigen exposure.
·
The lifetime prevalence of anaphylaxis is
currently estimated at 0.05-2 % in the USA and ~3 % in Europe. Several
population-specific studies have noted a rise in the incidence, particularly in
hospitalizations and ER visits due to anaphylaxis.
Thelansis’s “Anaphylaxis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Anaphylaxis
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Anaphylaxis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Anaphylaxis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment